{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:41:27Z","timestamp":1790260887676,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0612-6","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:59:03Z","timestamp":1526605143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Carmela","family":"De Santo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Beggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bessudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-0047","authenticated-orcid":false,"given":"Francis","family":"Mussai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/978-3-319-40618-3_47","volume-title":"AJCC cancer staging manual","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR. Melanoma of the skin. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC cancer staging manual. New York: Springer International Publishing; 2017. p. 563\u201385."},{"issue":"11","key":"612_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/ni.1942","volume":"11","author":"C De Santo","year":"2010","unstructured":"De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol. 2010;11(11):1039\u201346.","journal-title":"Nat Immunol"},{"issue":"19","key":"612_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"8","key":"612_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"612_CR5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191\u20136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"612_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ijc.30051","volume":"139","author":"L Fultang","year":"2016","unstructured":"Fultang L, Vardon A, De Santo C, Mussai F. Molecular basis and current strategies of therapeutic arginine depletion for cancer. Int J Cancer. 2016;139(3):501\u20139.","journal-title":"Int J Cancer"},{"issue":"15","key":"612_CR7","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","volume":"125","author":"F Mussai","year":"2015","unstructured":"Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, et al. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood. 2015;125(15):2386\u201396.","journal-title":"Blood"},{"issue":"1","key":"612_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/0008-5472.CAN-06-1945","volume":"67","author":"PN Cheng","year":"2007","unstructured":"Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67(1):309\u201317.","journal-title":"Cancer Res"},{"issue":"1","key":"612_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-012-9807-9","volume":"31","author":"T Yau","year":"2013","unstructured":"Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J, et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Investig New Drugs. 2013;31(1):99\u2013107.","journal-title":"Investig New Drugs"},{"issue":"2","key":"612_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s10637-014-0200-8","volume":"33","author":"T Yau","year":"2015","unstructured":"Yau T, Cheng PN, Chan P, Chen L, Yuen J, Pang R, et al. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Investig New Drugs. 2015;33(2):496\u2013504.","journal-title":"Investig New Drugs"},{"issue":"2","key":"612_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1755-148X.2010.00798.x","volume":"24","author":"TL Lam","year":"2011","unstructured":"Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, et al. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res. 2011;24(2):366\u201376.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"612_CR12","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/ijc.31170","volume":"142","author":"C De Santo","year":"2017","unstructured":"De Santo C, Booth S, Vardon A, Cousins A, Tubb V, Perry T, et al. The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100. Int J Cancer. 2017;142(7):1490\u2013502.","journal-title":"Int J Cancer"},{"issue":"1","key":"612_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","volume":"3","author":"K Szlosarek","year":"2017","unstructured":"Szlosarek K, Steel JP, Nolan L, Gilligan D, Taylor P, Spicer J, et al. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomised clinical trial. JAMA Oncol. 2017;3(1):58\u201366.","journal-title":"JAMA Oncol"},{"issue":"2","key":"612_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10637-012-9862-2","volume":"31","author":"PA Ott","year":"2013","unstructured":"Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, et al. Phase I\/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investig New Drugs. 2013;31(2):425\u201334.","journal-title":"Investig New Drugs"},{"key":"612_CR15","unstructured":"Rasco D, Eckhardt S, Davar D, Lewis K, Lara-Guerra H., Alters E. et al. Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumours. AACR Abstract CT030\/23. \n                    http:\/\/www.abstractsonline.com\/pp8\/#!\/4562\/presentation\/11181\n                    \n                  ."},{"issue":"48","key":"612_CR16","doi-asserted-by":"publisher","first-page":"20429","DOI":"10.1073\/pnas.0905139106","volume":"106","author":"D Bogunovic","year":"2009","unstructured":"Bogunovic D, O\u2019Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survivial. Proc Natl Acad Sci U S A. 2009;106(48):20429\u201334.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0612-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T19:11:50Z","timestamp":1558120310000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0612-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0612-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"assertion":[{"value":"14 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In accordance with the Declaration of Helsinki, patient samples were obtained after written, informed consent. South Central-Hampshire Regional Ethics Committee (10\/H0501\/39) and local hospital trust research approval for the study was granted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient and study members have provided consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"68"}}